ePrints

Adjuvant chemotherapy for perihilar cholangiocarcinoma: A population-based comparative cohort study

Lookup NU author(s): Professor Derek Manas, Steven White

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2021Background: Data supporting routine use of adjuvant chemotherapy (AC) compared to no AC (noAC) for perihilar cholangiocarcinoma (hCCA) is unclear. This study aimed to determine whether AC improves long-term survival following resection for hCCA. Methods: Patients receiving resection for hCCA followed by AC or no AC from 2010 to 2016 were identified from the National Cancer Database (NCDB). Propensity score matching (PSM) and Cox regression was performed to account for selection bias and analyze impact of AC on overall survival. Results: Of 924 (56%) noAC and 719 (44%) AC, 320 noAC and 320 AC patients remained after PSM. After matching, AC was associated with improved survival (median: 28.2 vs 19.9 months, p < 0.001), which remained after multivariable adjustment (HR: 0.61, CI95%: 0.50–0.75, p < 0.001). On multivariable interaction analyses, the benefit of AC over no AC persisted irrespective of nodal status: N0 (HR: 0.62, CI95%: 0.41–0.92, p = 0.019), N1 (HR: 0.52, CI95%: 0.36–0.75, p = 0.001), N2 (HR: 0.31, CI95%: 0.11–0.90, p = 0.032), Nx (HR: 0.22, CI95%: 0.09–0.55, p = 0.001) and margin status: R0 (HR: 0.74, CI95%: 0.57–0.97, p = 0.026), R1 (HR: 0.31, CI95%: 0.21–0.47, p < 0.001). Stratified analysis by nodal, margin and AC status demonstrated consistent results. Conclusion: AC following resection for hCCA was associated with improved survival in this study, even in margin-negative and node-negative disease. These findings suggest incorporation of AC into multimodality therapy for hCCA in all cases, where appropriate.

Publication metadata

Author(s): Kamarajah SK, Al-Rawashdeh W, Parente A, Atherton P, Salti GI, Dahdaleh FS, Manas D, Hilal MA, White SA

Publication type: Article

Publication status: Published

Journal: European Journal of Surgical Oncology

Year: 2022

Volume: 48

Issue: 6

Pages: 1300-1308

Print publication date: 01/06/2022

Online publication date: 10/12/2021

Acceptance date: 02/12/2021

ISSN (print): 0748-7983

ISSN (electronic): 1532-2157

Publisher: W.B. Saunders Ltd

URL: https://doi.org/10.1016/j.ejso.2021.12.002

DOI: 10.1016/j.ejso.2021.12.002

Altmetrics

Share